Atrial fibrillation raises stroke risk fivefold. But what if blood thinners are too dangerous after a brain bleed or major fall? A new monthly injection, abelacimab, may prevent strokes without the bleeding risk of traditional anticoagulants. Is this the future for AFib patients who can’t take blood thinners? Cardiologist Dr. Alain Bouchard discusses this groundbreaking drug with Dr. Charles V. Pollack, a consultant clinical scientist and professional educator with Novartis, owner of abelac...
All content for MyHeart.net is the property of Dr. Alain Bouchard and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Atrial fibrillation raises stroke risk fivefold. But what if blood thinners are too dangerous after a brain bleed or major fall? A new monthly injection, abelacimab, may prevent strokes without the bleeding risk of traditional anticoagulants. Is this the future for AFib patients who can’t take blood thinners? Cardiologist Dr. Alain Bouchard discusses this groundbreaking drug with Dr. Charles V. Pollack, a consultant clinical scientist and professional educator with Novartis, owner of abelac...
Alcohol – it's a ubiquitous part of social gatherings, celebrations, and even daily routines for many. Yet, amidst the conviviality, it's crucial to understand the delicate balance between indulgence and moderation when it comes to alcohol consumption. Dr Alain Bouchard, MD discusses with Dr. Martha Gulati, Director of Prevention & Associate Director of the Barbra Streisand Women’s Heart Center, and the President-Elect of the American Society for Preventive Cardiology.
MyHeart.net
Atrial fibrillation raises stroke risk fivefold. But what if blood thinners are too dangerous after a brain bleed or major fall? A new monthly injection, abelacimab, may prevent strokes without the bleeding risk of traditional anticoagulants. Is this the future for AFib patients who can’t take blood thinners? Cardiologist Dr. Alain Bouchard discusses this groundbreaking drug with Dr. Charles V. Pollack, a consultant clinical scientist and professional educator with Novartis, owner of abelac...
